Swiss National Bank’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $4.85M | Buy |
168,800
+7,000
| +4% | +$201K | ﹤0.01% | 1317 |
|
2025
Q1 | $5.43M | Buy |
161,800
+2,400
| +2% | +$80.5K | ﹤0.01% | 1213 |
|
2024
Q4 | $8.15M | Buy |
159,400
+28,500
| +22% | +$1.46M | 0.01% | 1044 |
|
2024
Q3 | $6.69M | Buy |
130,900
+600
| +0.5% | +$30.7K | ﹤0.01% | 1148 |
|
2024
Q2 | $5.84M | Buy |
130,300
+3,800
| +3% | +$170K | ﹤0.01% | 1178 |
|
2024
Q1 | $5.92M | Buy |
126,500
+22,300
| +21% | +$1.04M | ﹤0.01% | 1186 |
|
2023
Q4 | $3.71M | Sell |
104,200
-12,200
| -10% | -$434K | ﹤0.01% | 1470 |
|
2023
Q3 | $3.46M | Buy |
116,400
+34,200
| +42% | +$1.02M | ﹤0.01% | 1506 |
|
2023
Q2 | $1.48M | Buy |
82,200
+900
| +1% | +$16.2K | ﹤0.01% | 2081 |
|
2023
Q1 | $1.31M | Sell |
81,300
-9,500
| -10% | -$153K | ﹤0.01% | 2088 |
|
2022
Q4 | $1.66M | Buy |
90,800
+2,800
| +3% | +$51.2K | ﹤0.01% | 2016 |
|
2022
Q3 | $1.73M | Hold |
88,000
| – | – | ﹤0.01% | 1971 |
|
2022
Q2 | $1.64M | Buy |
88,000
+9,300
| +12% | +$173K | ﹤0.01% | 2056 |
|
2022
Q1 | $1.73M | Buy |
78,700
+7,700
| +11% | +$169K | ﹤0.01% | 2120 |
|
2021
Q4 | $2.02M | Buy |
71,000
+21,400
| +43% | +$608K | ﹤0.01% | 2055 |
|
2021
Q3 | $1.04M | Hold |
49,600
| – | – | ﹤0.01% | 2420 |
|
2021
Q2 | $935K | Buy |
49,600
+12,000
| +32% | +$226K | ﹤0.01% | 2505 |
|
2021
Q1 | $575K | Buy |
37,600
+1,400
| +4% | +$21.4K | ﹤0.01% | 2446 |
|
2020
Q4 | $511K | Hold |
36,200
| – | – | ﹤0.01% | 2458 |
|
2020
Q3 | $567K | Hold |
36,200
| – | – | ﹤0.01% | 2334 |
|
2020
Q2 | $634K | Buy |
36,200
+17,400
| +93% | +$305K | ﹤0.01% | 2316 |
|
2020
Q1 | $276K | Buy |
18,800
+900
| +5% | +$13.2K | ﹤0.01% | 2360 |
|
2019
Q4 | $449K | Hold |
17,900
| – | – | ﹤0.01% | 2443 |
|
2019
Q3 | $269K | Hold |
17,900
| – | – | ﹤0.01% | 2469 |
|
2019
Q2 | $448K | Buy |
+17,900
| New | +$448K | ﹤0.01% | 2446 |
|